Understanding the operative anatomy of liver transplantation — recipient hepatectomy, the anhepatic phase, and graft implantation — makes post-operative management and complication recognition significantly more intuitive.
Describe the major operative steps of orthotopic liver transplantation including vascular anastomoses and biliary reconstruction
Identify common early post-transplant surgical complications (hepatic artery thrombosis, biliary leak) and their management
Explain the principles of deceased donor versus living donor graft selection and the trade-offs of each
24 min · 5 sectionsTransplant Medicine
Reading mode
On this page
01Donor Types
02Operative Phases
03Early Post-Op Complications
04First 48 Hours Monitoring
05Clinical Application
Progress0/5
Liver grafts are sourced from four donor categories. Donor type influences graft quality, ischemia risk, and long-term outcomes — particularly biliary complications.
Type
Details
Deceased Donor Brain Death (DBD)
Gold standard; optimal graft quality; longest operative and outcome experience; warm ischemia time is minimal
Deceased Donor Circulatory Death (DCD)
Donation after cardiac death; expanding use due to organ shortage; increased risk of ischemic cholangiopathy versus DBD, owing to prolonged warm ischemia time affecting the biliary endothelium
Living Donor (LDLT)
Right lobe most common in adult recipients; left lateral segment for pediatric recipients; donor safety is paramount — donor mortality approximately 0.1–0.8% for right lobe donation (A2ALL multicenter study found 0.8% in 393 donors, PMID 18505689); informed consent should reflect the upper bound of published estimates; rigorous donor selection required
Split Liver
One deceased donor liver split for two recipients — typically right lobe to an adult and left lateral segment to a pediatric recipient; maximizes organ utilization
Quick recall
1/2
Why does DCD donation carry a higher risk of ischemic cholangiopathy compared to DBD?
Tap to reveal →
Liver transplantation proceeds in three sequential phases. Familiarity with each phase allows trainees to anticipate intraoperative events, understand anesthesia management decisions, and recognize why specific post-operative complications arise at particular time points.
Recipient Hepatectomy
Highest bleeding risk
The native diseased liver is removed. Meticulous hemostasis and vascular control are essential — coagulopathy is common in end-stage liver disease, and bleeding in this phase carries significant morbidity.
Bilateral subcostal incision ± midline extension (Mercedes incision) — provides wide exposure to the upper abdomen
Ligament mobilization — division of the falciform, triangular, and coronary ligaments to free the liver from its attachments
Vascular and biliary dissection — isolation and control of the portal vein, hepatic artery (typically the proper hepatic artery), and common bile duct (CBD)
IVC isolation — identification and preparation of the retrohepatic inferior vena cava above and below the liver for clamping
Piggyback Technique (now standard at most centres)
The recipient's retrohepatic IVC is preserved rather than excised. The three hepatic veins are divided and the donor liver's IVC is anastomosed to the recipient's common hepatic vein ostium (typically side-to-side). This approach avoids full IVC clamping, preserves venous return to the right heart, and is hemodynamically superior — reducing the need for venovenous bypass. The anastomosis sits at the confluence of the hepatic veins rather than requiring two separate caval anastomoses.
Venovenous bypass — a circuit that shunts portal and systemic venous blood to the axillary vein during IVC clamping, preventing hemodynamic collapse — was historically common but is largely supplanted by the piggyback technique at most transplant centers.
Early recognition of post-transplant complications requires integrating lab trends, imaging findings, and clinical trajectory. The timing of a complication is one of the most useful localizing features.
Critical Teaching Point — Hepatic Artery Thrombosis (HAT)
HAT is the most feared early vascular complication of liver transplantation. The biliary tree depends entirely on hepatic arterial supply — there is no portal venous collateral to the bile ducts in the transplanted liver. HAT therefore causes biliary ischemia that can manifest as biliary leak, cholangitis, sepsis, or late ischemic strictures. Any suspicion requires urgent Doppler ultrasonography. Retransplantation is often required.
Why the bile ducts are the collateral casualty of hepatic artery thrombosis
Complication
Timing
Key Features
Primary Non-Function (PNF)
Hours–3 days
Immediate graft failure; AST/ALT >5,000 IU/L, INR not recovering, worsening encephalopathy, hemodynamic instability; retransplantation is the only definitive option; risk factors include DCD donor, prolonged cold ischemia time, and highly steatotic graft (>60% macrosteatosis)
Early Allograft Dysfunction (EAD)
Days 2–7
Suboptimal but not failed graft; defined as: peak AST or ALT >2,000 IU/L on days 1–7, or total bilirubin ≥10 mg/dL on day 7, or INR ≥1.6 on day 7; most grafts recover without retransplant with supportive management
Hepatic Artery Thrombosis (HAT)
Within 30 days
Most feared early complication; incidence ~2.9% in adults and ~8.3% in children (overall ~4.4%); causes biliary ischemia because bile ducts depend solely on hepatic arterial supply; may present as biliary leak, sepsis, rising LFTs, or be asymptomatic initially; urgent Doppler USS required; retransplant often necessary; risk factors include technical anastomotic issues, hypercoagulable state, hepatic artery size mismatch
Portal Vein Thrombosis (PVT)
Within 30 days
Less common than HAT; presents with rising transaminases, new or worsening ascites, splenomegaly; diagnosis by Doppler USS; may be amenable to thrombolysis, anticoagulation, or surgical revision; prior portal vein thrombosis in recipient is a significant risk factor
Biliary Leak
Days 3–14
Most common early biliary complication; often at T-tube exit site or the biliary anastomosis; clinical features: bile-tinged or bile-stained drain fluid, rising bilirubin, abdominal pain, peritoneal signs if large; managed with ERCP ± biliary stenting for anastomotic leaks; surgical re-exploration if ERCP fails or peritonitis develops
Biliary Stricture
Weeks–months
Anastomotic stricture (most common): localized to the biliary anastomosis; usually ERCP-amenable with balloon dilation ± stenting; Ischemic/non-anastomotic stricture: associated with HAT or DCD donor ischemia; diffuse intrahepatic biliary tree involvement; often requires retransplantation
Acute Cellular Rejection (ACR)
Days 5–30
Fever, rising transaminases and bilirubin, eosinophilia; diagnosis confirmed on liver biopsy using Banff criteria (portal inflammation + endotheliitis + bile duct damage, each scored 1–3; rejection activity index ≥4 indicates rejection); first-line treatment: pulse-dose IV methylprednisolone (typically 500–1000 mg daily × 3 days); steroid-refractory cases: lymphocyte-depleting agents
The first 48 hours after transplant are the highest-acuity window. The monitoring strategy is designed to catch the earliest signals of graft dysfunction, vascular complications, and metabolic derangements before they become irreversible.
Hourly urine output monitored
Oliguria suggests hemodynamic compromise, ATN from ischemia-reperfusion, or calcineurin inhibitor nephrotoxicity (tacrolimus)
Hourly
LFT trend — AST, ALT, bilirubin, INR every 6–12 hours
Rising values after initial decline are the key warning sign distinguishing normal post-reperfusion enzyme release from ongoing dysfunction
q6–12h
Doppler USS hepatic artery, portal vein, hepatic veins on POD 1
Mandatory at most transplant centers — the only way to reliably exclude HAT in the early post-operative window; confirms patency before ICU discharge
POD 1 mandatory
Drain output assessed — character and volume
Bile-tinged fluid raises concern for biliary leak; sanguineous output raises concern for post-operative hemorrhage; drain amylase if biliary leak suspected
Ongoing
Tacrolimus level checked (started POD 1)
Target trough level varies by center and recipient risk profile (often 8–12 ng/mL early); subtherapeutic levels increase rejection risk; supratherapeutic levels cause nephrotoxicity and neurotoxicity
Daily
Glucose monitoring — hourly in ICU
The new liver resumes gluconeogenesis and glycogen synthesis, but function is variable early post-operatively; hypoglycemia and hyperglycemia both occur
Hourly ICU
0 of 6 complete
Quick recall
1/2
Why is Doppler USS of the hepatic artery mandatory on POD 1 rather than only when clinically suspected?
Tap to reveal →
Clinical Case Vignette
A 52-year-old woman with alcohol-associated cirrhosis (MELD 3.0 34) undergoes orthotopic liver transplantation from a DBD donor. The procedure includes recipient hepatectomy using the piggyback technique, with anhepatic time of 74 minutes. She is extubated on POD 1 and transferred to the transplant floor on POD 2.
POD 2 Labs: AST 4,800 IU/L · ALT 3,600 IU/L · TBili 6.4 mg/dL · INR 2.1 (worsening from 1.8 on POD 1) · Cr 2.6 mg/dL (baseline 0.9) · UO 12 mL/hr × 4h · Surgical drain: 180 mL bile-colored fluid overnight
Work through the management step by step before the answers are revealed.
References
Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation. N Engl J Med. 1989;321(15):1014-1022. PubMed 2674716
Olthoff KM, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010;16(8):943-949. PubMed 20677285
Te HS, Agopian VG, Demetris AJ, et al. AASLD-AST practice guideline on adult liver transplantation: diagnosis and management of graft-related complications. Liver Transpl. 2026;32(3):444-490. PubMed 40844852(current AASLD-AST guideline)
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol. 2016;64(2):433-485. PubMed 26597456
Ghobrial RM, Freise CE, Trotter JF, et al. Donor morbidity after living donation for liver transplantation. Gastroenterology. 2008;135(2):468-476. doi:10.1053/j.gastro.2008.04.018. PubMed 18505689(A2ALL cohort — 393 donors; source of the donor-mortality figure)